ArticleCancer communications (London, England)2024
Discovering genetic biomarkers for targeted cancer therapeutics with eXplainable Artificial Intelligence.
Debaditya Chakraborty, Elizabeth Gutierrez-Chakraborty, Cristian Rodriguez-Aguayo, Hakan Başağaoğlu, Gabriel Lopez-Berestein, Paola Amero
Abstract readLetter
In one paragraphArticle in Cancer communications (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
6 authors.
Debaditya ChakrabortySchool of Civil and Environmental Engineering and Construction Management, The University of Texas at San Antonio, San Antonio, Texas, USA.ORCID 0000-0002-2165-9440 Elizabeth Gutierrez-ChakrabortyDepartment of Cell Systems and Anatomy, University of Texas Health Science Center, San Antonio, Texas, USA.
Cristian Rodriguez-AguayoDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Hakan BaşağaoğluEdwards Aquifer Authority, San Antonio, Texas, USA.
Gabriel Lopez-BeresteinDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Paola AmeroDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MTropism Enhanced Oncolytic Adenovirus for the Treatment of Brain TumorsP50CA127001 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Juan Fueyo · 2008 to 2026
$41.2MU.T. M. D. Anderson Cancer Center SPORE in Ovarian CancerP50CA217685 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BAST, ROBERT C, SOOD, ANIL K · 2017 to 2021
$7.9MTargeted therapeutics for ovarian cancer and its microenvironment - treatment and theoretical modelingU01CA213759 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LOPEZ-BERESTEIN, GABRIEL · 2017 to 2021
$2.5MBrain SPORE Career Enhancement Program and NCI P50CA127001National Institutes of Health/National Cancer Institute 5U01CA213759-02National Institutes of Health/National Cancer Institute P30CA016672National Science Foundation CHE-1411859NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA127001NCI NIH HHS P50 CA217685NCI NIH HHS U01 CA213759SPORE Career Enhancement Program and NCI P50CA217685
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Artificial IntelligenceNeoplasmsBiomarkers, TumorGenetic MarkersHumansMolecular Targeted TherapyBiomarkers, TumorGenetic Markers
Identifiers
PMID38566430
PMCPMC11110951
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390